191 related articles for article (PubMed ID: 37258094)
1. Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours.
Dickerson LK; Carter JA; Kohli K; Pillarisetty VG
Gut; 2023 Aug; 72(8):1592-1606. PubMed ID: 37258094
[TBL] [Abstract][Full Text] [Related]
2. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.
Mortezaee K; Majidpoor J
Cell Oncol (Dordr); 2022 Jun; 45(3):333-353. PubMed ID: 35587857
[TBL] [Abstract][Full Text] [Related]
3. Harnessing cytokines and chemokines for cancer therapy.
Propper DJ; Balkwill FR
Nat Rev Clin Oncol; 2022 Apr; 19(4):237-253. PubMed ID: 34997230
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic and epigenomic approaches to untangle the enigma of IL-10 blockade in oncology.
Elemam NM; Mekky RY; Rashid G; Braoudaki M; Youness RA
Expert Rev Mol Med; 2024 Jan; 26():e1. PubMed ID: 38186186
[TBL] [Abstract][Full Text] [Related]
5. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Zhou T; Damsky W; Weizman OE; McGeary MK; Hartmann KP; Rosen CE; Fischer S; Jackson R; Flavell RA; Wang J; Sanmamed MF; Bosenberg MW; Ring AM
Nature; 2020 Jul; 583(7817):609-614. PubMed ID: 32581358
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Brain Tumours: Lessons from the Immune Microenvironment.
Yao B; Delaidelli A; Vogel H; Sorensen PH
Curr Oncol; 2023 May; 30(5):5024-5046. PubMed ID: 37232837
[TBL] [Abstract][Full Text] [Related]
7. The IL-2 cytokine family in cancer immunotherapy.
Sim GC; Radvanyi L
Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and applications of interleukins in cancer immunotherapy.
Anestakis D; Petanidis S; Kalyvas S; Nday CM; Tsave O; Kioseoglou E; Salifoglou A
Int J Mol Sci; 2015 Jan; 16(1):1691-710. PubMed ID: 25590298
[TBL] [Abstract][Full Text] [Related]
12. Biological effects of IL-21 on immune cells and its potential for cancer treatment.
Ma M; Xie Y; Liu J; Wu L; Liu Y; Qin X
Int Immunopharmacol; 2024 Jan; 126():111154. PubMed ID: 37977064
[TBL] [Abstract][Full Text] [Related]
13. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
[TBL] [Abstract][Full Text] [Related]
14. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E
Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
[TBL] [Abstract][Full Text] [Related]
15. Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10.
Rallis KS; Corrigan AE; Dadah H; George AM; Keshwara SM; Sideris M; Szabados B
Anticancer Res; 2021 Jul; 41(7):3247-3252. PubMed ID: 34230118
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities.
Laumont CM; Banville AC; Gilardi M; Hollern DP; Nelson BH
Nat Rev Cancer; 2022 Jul; 22(7):414-430. PubMed ID: 35393541
[TBL] [Abstract][Full Text] [Related]
17. The tumour immune landscape and its implications in cutaneous melanoma.
Attrill GH; Ferguson PM; Palendira U; Long GV; Wilmott JS; Scolyer RA
Pigment Cell Melanoma Res; 2021 May; 34(3):529-549. PubMed ID: 32939993
[TBL] [Abstract][Full Text] [Related]
18. Role of immune microenvironment in gastrointestinal stromal tumours.
Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
Habanjar O; Bingula R; Decombat C; Diab-Assaf M; Caldefie-Chezet F; Delort L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835413
[TBL] [Abstract][Full Text] [Related]
20. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
